Zacks Research Forecasts Weaker Earnings for DENTSPLY SIRONA

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at Zacks Research cut their Q3 2026 EPS estimates for DENTSPLY SIRONA in a research note issued to investors on Thursday, August 27th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.31 per share for the quarter, down from their prior forecast of $0.37. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.41 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q4 2026 earnings at $0.40 EPS, FY2026 earnings at $1.50 EPS, Q2 2027 earnings at $0.38 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.39 EPS, FY2027 earnings at $1.50 EPS, Q1 2028 earnings at $0.35 EPS, Q2 2028 earnings at $0.41 EPS and FY2028 earnings at $1.64 EPS.

A number of other analysts also recently issued reports on XRAY. Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a research report on Monday, August 10th. Piper Sandler upped their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Finally, Mizuho dropped their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.54.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.04 on Friday. DENTSPLY SIRONA has a 52 week low of $9.40 and a 52 week high of $14.86. The stock’s fifty day moving average is $12.08 and its two-hundred day moving average is $11.75. The company has a market capitalization of $2.20 billion, a P/E ratio of -4.01, a P/E/G ratio of 1.38 and a beta of 0.85. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several large investors have recently added to or reduced their stakes in the business. Eurizon Capital SGR S.p.A. purchased a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the first quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares during the period. Nykredit A S acquired a new stake in shares of DENTSPLY SIRONA in the second quarter valued at $38,000. Finally, Farther Finance Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 119.1% in the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after acquiring an additional 2,051 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Brian T. Gladden acquired 9,985 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. This represents a 19.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.